Cytokinetics MYQORZO (Aficamten) Takes Center Stage at European Society of Cardiology Heart Failure 2026 Congress

Key Takeaways

• Cytokinetics will present nine studies on MYQORZO (aficamten) at the European Society of Cardiology Heart Failure 2026 Congress
• Eight presentations focus on the recently approved treatment for obstructive hypertrophic cardiomyopathy (oHCM)
• MYQORZO has received regulatory approval from FDA, European Commission, and China’s NMPA for treating symptomatic oHCM in adults

---

Cytokinetics announced nine upcoming presentations at the European Society of Cardiology Heart Failure 2026 Congress, with eight studies focusing on MYQORZO® (aficamten), the company’s recently approved treatment for obstructive hypertrophic cardiomyopathy (oHCM).

Major Regulatory Milestone

MYQORZO has achieved significant regulatory success, receiving approval from three major health authorities: the U.S. Food and Drug Administration, European Commission, and China National Medical Products Administration. The drug is indicated for treating adults with symptomatic obstructive hypertrophic cardiomyopathy.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

How MYQORZO Works

As an allosteric and reversible inhibitor of cardiac myosin motor activity, MYQORZO represents a novel therapeutic approach for oHCM patients. The drug works by reducing cardiac contractility through myosin inhibition, addressing the underlying pathophysiology of the condition.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Congress Presentations

The European Society of Cardiology Heart Failure 2026 Congress will feature comprehensive data on MYQORZO, including a late-breaking science oral presentation. These presentations are expected to provide additional clinical evidence supporting the drug’s efficacy and safety profile in oHCM patients.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market Impact

The multiple presentations at this prestigious cardiology congress underscore Cytokinetics’ commitment to advancing treatment options for hypertrophic cardiomyopathy patients. With regulatory approvals secured in major markets, MYQORZO is positioned to address a significant unmet medical need in the cardiovascular space.

The comprehensive presentation schedule demonstrates the robust clinical data package supporting MYQORZO’s therapeutic profile and may influence treatment guidelines and physician adoption patterns across Europe and globally.

---

Frequently Asked Questions

What is MYQORZO used to treat?

MYQORZO (aficamten) is approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle becomes abnormally thick and blocks blood flow.

Where is MYQORZO approved for use?

MYQORZO has received regulatory approval from the U.S. FDA, European Commission, and China National Medical Products Administration, making it available in major global markets.

How does MYQORZO work differently from other heart medications?

MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity, representing a novel mechanism that directly targets the underlying cause of oHCM by reducing excessive cardiac contractility.

Related coverage

• KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
• EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors
• European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma